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Abstract: 
Grafting of cell-seeded alginate capillary hydrogels into a spinal cord lesion site provides an 
axonal bridge while physically directing regenerating axonal growth in a linear pattern. 
However, without an additional growth stimulus, bridging axons fail to extend into the distal host 
spinal cord. Here we examined whether a combinatory strategy would support regeneration of 
descending axons across a cervical (C5) lateral hemisection lesion in the rat spinal cord. 
Following spinal cord transections, Schwann cell (SC)-seeded alginate hydrogels were grafted to 
the lesion site and AAV5 expressing brain-derived neurotrophic factor (BDNF) under control of 
a tetracycline-regulated promoter was injected caudally. In addition, we examined whether SC 
injection into the caudal spinal parenchyma would further enhance regeneration of descending 
axons to re-enter the host spinal cord. Our data show that both serotonergic and descending 
axons traced by biotinylated dextran amine (BDA) extend throughout the scaffolds. The number 
of regenerating axons is significantly increased when caudal BDNF expression is activated and 
transient BDNF delivery is able to sustain axons after gene expression is switched off. 
Descending axons are confined to the caudal graft/host interface even with continuous BDNF 
expression for 8 weeks. Only with a caudal injection of SCs, a pathway facilitating axonal 
regeneration through the host/graft interface is generated allowing axons to successfully re-enter 
the caudal spinal cord. 
 
 
 
 
 
 
 
 
 
Keywords: Alginate hydrogel, spinal cord injury, Schwann cells, brain-derived neurotrophic 
factor, axonal regeneration, regulated gene expression, biomaterial, AAV5 
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1. Introduction 
Axonal regeneration after injury of the mammalian spinal cord is very limited. This is due to an 
inhibitory microenvironment, cavitation and fibroglial scarring around the lesion site, an 
insufficient intrinsic growth capacity of adult neurons in the central nervous system (CNS), as 
well as a lack of suitable growth substrates and growth-stimulating factors [1, 2]. Several 
strategies including grafting of cells and/or biomaterials [3], delivery of growth factors and 
degradation of inhibitory matrix molecules [4], activation of an intrinsic growth program [5], and 
stabilization of growth cones and axonal cytoskeleton [6] have aimed to overcome these 
impediments. Of these approaches, biomaterials that can not only fill a lesion cavity, but can also 
provide a substrate for cellular grafting, physical guidance of regenerating axons and a vehicle 
for drug delivery are highly promising for cellular and molecular regenerative therapies [7].  
 
We have previously shown that anisotropic capillary hydrogels made from alginate, a natural 
biopolymer from the cell walls of brown algae and widely used in the food and pharmaceutical 
industry, are able to physically guide axons in vitro [8-10]. In the injured spinal cord, linear 
axonal growth in a rostro-caudal direction is enhanced when hydrogels are seeded with bone 
marrow stromal cells (BMSCs) and further amplified when BMSCs are genetically modified to 
overexpress the neurotrophin brain-derived neurotrophic factor (BDNF). However, axons fail to 
extend beyond the lesion site [11, 12]. The continuous expression of BDNF by cells within the 
scaffold may saturate the receptors of regenerating axons, which therefore fail to extend beyond 
the graft into the host tissue with lower BDNF levels. In addition, the limited integration of 
BMSCs into the spinal cord, and fibroglial scarring around the implant confine regenerating 
axons to the lesion site [11]. To address these issues, we explored Schwann cells as a more 
compatible cell candidate, along with distal growth factor delivery to chemotropically attract 
bridging axons into the host tissue. 
 
Schwann cells (SCs) support axonal growth in the injured spinal cord and are currently examined 
in clinical trials as an autologous cellular graft [13]. After transplantation, SCs can myelinate 
re-growing and spared, demyelinated axons to support their maintenance and elongation [14-16]. 
In addition, SCs secrete neurotrophic factors including nerve growth factor (NGF), 
neurotrophin-3 (NT-3), glial cell line-derived neurotrophic factor (GDNF) and ciliary 
neurotrophic factor (CNTF) [17-19] as well as extracellular matrix molecules (e.g. laminin, 
fibronectin and collagen) [20, 21], which are known to protect spared tissues and facilitate 
axonal growth. Furthermore, several studies have demonstrated that SC grafts may serve as 
bridges within the lesion and intermingle with astrocytic processes, making the graft/host 
interface more permissive for axonal extension [4, 22]. 
 
Brain-derived neurotrophic factor (BDNF) is one of the best characterized neurotrophins 
promoting neural protection and axonal regeneration after SCI [23-26]. Increasing BDNF levels 
in the host parenchyma by overexpression or ectopic delivery can overcome the inhibitory 
effects of proteoglycans in the scar and stimulate axonal growth beyond the lesion edge [27, 28]. 
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Transient BDNF delivery by genetically modified fibroblasts can sustain regenerated axons 
within the lesion site [29], however continuous BDNF overexpression may induce spasticity-like 
symptoms and deterioration of functional outcomes [30, 31]. A regulated delivery system is 
therefore needed. Tetracycline-regulated expression systems containing a tetracycline 
(Tet)-responsive promoter and transactivator have been used extensively to stringently control 
the expression of target genes [32, 33]. Two systems (Tet-off and Tet-on) have been described 
depending on whether gene expression is downregulated or upregulated in the presence of Tet. 
For clinical translation requiring transient gene expression, the Tet-on system has the major 
advantage that administration of Tet is only required during the period of desired gene 
expression [29]. 
 
In the present study, we applied a combinatorial approach of alginate hydrogels seeded with 
syngeneic SCs and a distal gradient of tet-regulated viral BDNF expression to promote 
descending axonal growth through the lesion. Our data show that the number of regenerating 
axons is enhanced by transient viral neurotrophin expression, and in combination with SC 
injection into the host parenchyma, descending axons extend across the hydrogel into the distal 
spinal parenchyma. 
 
2. Materials and Methods 
2.1.Production of capillary alginate hydrogels 
Alginate hydrogels with longitudinally aligned circular capillaries were prepared as previously 
described [8, 10, 11]. Ultrapure sodium alginate (UP MVG, Novamatrix FMC) with medium 
viscosity (>200mPa·s) and 70% guluronic acid content was dissolved in ion-free water 
(Millipore) at a concentration of 2% (w/w) before being filtered through a 0.2 µm 
polyethersulfone membrane (VWR). The alginate solution (65g) was transferred into an 
anisotropic hydrogel by covering it with 20 ml of 1M Zn(NO3)2 in an anodized cylindrical 
aluminum mold (diameter 5cm; Schuett-Biotec) and a minimum diffusion time of 36h. The gel 
was rinsed with deionized water to remove excessive electrolytes and the top 5 mm layer without 
capillary structures was cut off to obtain a 15 mm thick gel block. For chemical cross-linking, the 
gel block was dehydrated in increasing concentrations of acetone (25%, 50%, 75%, 100%) 
followed by dry acetone containing 0.1M hexamethylene-di-isocyanate (HDI; VWR). Fixed gel 
blocks were rinsed in 0.1M HCl to exchange cross-linking Zn2+cations and washed in purified 
water until a neutral pH was reached. Afterwards, the gel was cut into 2×2×1.3 mm cubes (length 
of capillaries: 2 mm) using a vibratome (Leica) and stored in 70% ethanol. Each scaffold was 
visualized under light microscopy (Olympus) to analyze dimension and density of capillaries. 
Only blocks with evenly distributed and straight capillaries parallel to the long axis of the 
scaffolds were selected for in vivo experiments. One day before implantation, alginate hydrogel 
scaffolds were transferred into Dulbecco's phosphate-buffered saline (D’PBS) for washing and 
stored overnight. The scaffolds used for implantation showed longitudinally aligned and evenly 
distributed capillaries at a density of 61 ± 4 channels/mm2 with a capillary diameter of 64.4 ± 6.2 
µm (Fig. 1A) and a wall/channel ratio of approximately 4:1. 
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2.2. Production and characterization of regulated adeno-associated viral (AAV) vectors 
The basic vector rAAV-rtTA-GFP carrying a tetracycline (Tet)-regulated bi-directional promoter 
(pTetbidiON) and the coding sequence for enhanced green fluorescence protein (GFP) has been 
described previously [34]. To further improve this vector, the original tet-responsive 
transactivator (rtTA) sequence [35] was replaced by rtTAV16, a mutated rtTA with improved 
doxycyline-sensitivity [36]. To obtain a BDNF Tet-regulated vector, the plasmid was digested 
with AgeI/NotI (Biolabs) to remove the GFP cDNA and an AgeI/NotI fragment containing the 
human BDNF cDNA was cloned into this site. For initial in vitro testing, plasmids were 
transfected into 293T cells using a calcium-phosphate transfection. Cells were treated with 1 
µg/ml doxycycline (Dox; Sigma-Aldrich) for 24h and the culture medium was collected for 
analysis of BDNF levels. The cells were fixed with 4% paraformaldehyde (PFA) and incubated 
with 0.25 µg/ml 4,6-diamidino-2-phenylndole (DAPI; Sigma Aldrich) to quantify the number of 
GFP expressing cells under a fluorescence microscope (IX81; Olympus).  
For in vivo experiments, the rAAV-rtTAV16 vectors were packaged into recombinant 
adeno-associated virus serotype 5 (rAAV5) capsids by the Gene Therapy Center Vector Core 
(University of North Carolina, USA). AAV5 has previously been shown to allow for more 
widespread expression in brain and spinal cord [37]. Viral titers as determined by quantitative 
polymerase chain reaction (qPCR) were: 1.5×1012 vg/ml for rAAV5-GFP 
(rAAV-rtTAV16-GFP), 2.3×1012 vg/ml for rAAV5-BDNF (rAAV-rtTAV16-BDNF). 
 
2.3.Primary cultures of SCs 
Highly purified SCs were prepared from sciatic nerves of wild-type (WT) Fischer 344 rats 
(Charles River) or GFP-transgenic Fischer 344 rats (F344-Tg(UBC-EGFP) F455Rrrc; Rat 
Resource and Research Center, Columbia, MO). Nerves were cut into 1 mm-long explants and 
cultured with Dulbecco's modified Eagle's medium (DMEM; Life Technologies) containing 10% 
fetal bovine serum (FBS) and 100 U/ml antibiotics (penicillin and streptomycin, Gibco). When 
migratory cells (primarily fibroblasts) around the explants reached confluence after 
approximately one week in culture, explants were transferred into a new dish with fresh cell 
culture medium. After 5-6 weeks, nerve explants were dissociated by 1.25 U/ml dispase 
(Worthington) and 0.05% collagenase XI (Sigma Aldrich) and replated in DMEM containing 
10% FBS, 20 µg/ml pituitary extract and 2µM forskolin (Sigma-Aldrich). Cells were passaged 
twice before transplantation. The purity of SCs evaluated by immunolabeling for the low affinity 
neurotrophin receptor p75 (mAB192MB hybridoma supernatants) and DAPI was 96-98%. 
 
2.4.Animal subjects and doxycycline treatment 
Adult female Fischer 344 rats (total n=73) weighing 150-200g were used in this study. National 
guidelines and the European Union Directive (2010/63/EU) were strictly followed for surgical 
procedures and animal care. Animals were housed in standard cages and had free access to water 
and food. Two days prior to surgery, animals were randomly divided into groups that were either 
treated with Dox in the drinking water (+Dox; 2 mg/ml in 5% sucrose) for the time indicated in 
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Table 1, in some cases followed by withdrawal of Dox. Control animals received 5% sucrose 
(-Dox) only throughout the experiment. 
 
2.5.Surgical procedures 
Animals were deeply anesthetized by intramuscular injection of a cocktail (2.5 ml/kg) of 
ketamine (62.5 mg/kg; Bremer Pharma), xylazine (3.175 mg/kg; Ecuphar) and acepromazine 
(0.625 mg/kg; Ceva). A laminectomy was performed at vertebra C4 (cervical spinal level C5), 
followed by a longitudinal incision of the dura to create a cervical spinal cord hemisection for 
hydrogel transplantation. After two lateral subdural spinal incisions spaced 1.5-2 mm apart, a 
block of spinal cord tissue at C5 was removed by alternately using micro-scissors and 
micro-aspiration (Fig. 1). Immediately prior to the transplantation, the scaffolds were pre-loaded 
with 2-3 µl (1×105 cells/µl) of SCs suspended in 1 mg/ml glucose in PBS and derived from WT 
or GFP-transgenic animals (Table 1). Scaffolds were carefully implanted into the lesion cavity 
ensuring that the capillary direction was parallel to the spinal cord axis and the scaffold closely 
embedded into the surrounding tissue. An agarose film (2×3 mm) was placed over the scaffold 
and a mixture of 2 µl fibrinogen (100 mg/ml; Sigma Aldrich) and 2 µl thrombin (400 U/ml; 
Sigma Aldrich) was used to cover the dural opening. AAV vectors (8 µl) were injected via a 
pulled glass capillary into the ipsilateral spinal cord 4 or 6 mm caudal to the lesion, 1 mm lateral 
to the midline, at a depth of 1.5 mm. This was based on a preliminary experiment, which 
indicated that rAAV5-GFP diffuses 4-6 mm away from the injection site in the intact spinal cord. 
Injections were performed at a speed of 0.5 µl/min using a Picospritzer (Parker Hannifin). In one 
group of animals, GFP-transgenic SCs (1×105 cells in 1 µl) were also injected into the spinal cord 
1 mm caudal to the lesion (Table 1). After each injection, the glass capillary was left in place for 
2 min and slowly withdrawn. Muscles were repositioned, sutured and the skin was stapled. To 
label descending propriospinal axons and possibly other axons of passage, 1 µl of 10% 
biotinylated dextran amine (BDA; MW 10,000kDa; Life Technologies) was injected at a depth 
of 1.5 mm, 1 mm lateral to the midline between C1 and C2 ipsilaterally to the lesion 3 or 7 
weeks later (one week before sacrifice). For post-operative treatment, all animals were injected 
subcutaneously twice a day with buprenorphine (30-40 µg/kg, Temgesic, Reckitt Benckiser) for 
two days and ampicillin (150 mg/kg, Ratiopharm) for 5-7 days to prevent infections. Carprofen 
(4-5 mg/kg, Rimadyl, Pfizer) was injected subcutaneously beyond 2 days post-surgery for further 
pain relieve as needed. All animals were fed with 2 ml high-energy nutrition drink (Fresubin, 
Fresenius Kabi) three times per day until their body weight started to increase. Dox (5 mg/ml) 
was mixed in the drink of designated groups. 
 
2.6.Characterization of BDNF expression in vivo 
Four weeks after grafting and virus injection, animals were deeply anesthetized and 
transcardially perfused with 50 ml of ice-cold 0.1M phosphate-buffered saline (PBS). The spinal 
cord ipsilateral to lesion as well as the biomaterial implants were carefully removed and 
immediately frozen at -80°C for further processing. In a pilot experiment, an 8 mm long segment 
adjacent to the lesion was used to assess the total amount of BDNF in the host spinal cord after 
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AAV5 injection (Table 1: GFP-Dox, n=3; GFP +Dox, n=3; BDNF -Dox, n=3; BDNF +Dox, 
n=4). For a more detailed analysis of BDNF levels, spinal cords collected from animals injected 
with rAAV5-BDNF and treated with Dox (n=6) or without Dox (n=4) were cut into 100 µm 
thick coronal sections on a cryostat (Zeiss) and consecutive series of 10 sections were pooled 
into 1 mm segments. BDNF levels were also measured within the scaffold in all of the animals 
described above. 
Samples were weighed before sonication in 40 µl/mg lysis buffer (PBS with 0.25% Triton 
X-100, 5mM EDTA, 0.5% BSA, 1mM PMSF, and 1 µl/ml aprotinin). After centrifugation at 
14,000 rpm at 4°C for 10 min, supernatants were collected for BDNF ELISA as previously 
described [29]. Briefly, rabbit anti-BDNF antibody (1:2000; Acris) was coated in 96-well plates 
while normal rabbit IgG was used as control. After 4 washes, plates were blocked with 3% 
bovine serum albumin (BSA; Sigma Aldrich) and diluted spinal cord tissue lysates were added. 
Serially diluted recombinant human BDNF (Biochrom) was used as standard. Plates were 
incubated overnight at 4°C, followed by 4 washes and overnight incubation with chicken 
anti-BDNF antibody (1:2500; Promega) under the same conditions. Plates were washed and 
incubated with anti-chicken IgY coupled to horseradish peroxidase (HRP, 1:1000; Promega) 
overnight. Additional washes were performed and ο-phenylenediamine (0.5 mg/ml; 
Sigma-Aldrich) was added as substrate for HRP detection. After 15 min, the reaction was 
terminated with10% H2SO4 and the absorption was detected by a spectrophotometer (Tecan) at 
490 nm wavelength. Absorption values of control wells coated with normal IgG were subtracted 
from wells coated with anti-BDNF antibody to exclude nonspecific binding. Diluted cell culture 
supernatants were analyzed using the same methods. 
 
2.7.Tissue preparation and immunohistochemistry 
Animals were deeply anesthetized and transcardially perfused with 100 ml ice-cold PBS, 
followed by 250 ml ice-cold 4% paraformaldehyde (PFA) in 0.1M phosphate buffer (PB). Brains 
and spinal cords were dissected, post-fixed in PFA for 1 hour and cryoprotected in 30% sucrose 
in 0.1M PB at 4°C. Horizontal sections were cut on a cryostat at 30 µm intervals from a 2.5 cm 
long block of spinal cord tissue centered around the grafts. Every 15th section was directly 
mounted onto the same glass slide for immunolabeling. 
For immunolabeling, sections were rinsed in tris-buffered saline (TBS) and blocked with 5% 
donkey serum / 0.25% Triton X-100 in TBS. Sections were incubated with different 
combinations of the following antibodies: rabbit anti-GFP (1:1000; Life Technologies), mouse 
anti-GFP (1:2000; Life Technologies), goat anti-GFP (1:1000; Rockland), guinea pig anti-glial 
fibrillary acidic protein (GFAP, 1:500; Progen), rabbit anti-GFAP (1:1000; Dako), goat 
anti-Olig2 (1:500; Santa Cruz), mouse anti-NeuN (1:200; Millipore), mouse anti-βIII-tubulin 
(1:750; Promega) and rabbit anti-5-hydroxytryptamine (5-HT, 1:2000; Immunostar), 
streptavidin-Alexa 594 (to detect the anterograde tracer BDA, 1:500; Jackson Immuno 
Research). On the following day, secondary antibodies made in donkey including anti-rabbit and 
anti-mouse IgG coupled to Alexa 488, or Alexa 594 (all 1:300; Invitrogen) and anti-guinea pig 
IgG coupled to Cy5 (1:500; Jackson Immuno Research) were used and co-incubated with 0.25 
  
Liu et al.  
 8 
µg/ml DAPI to visualize nuclei. Sections were dried and coverslipped with Fluoromount G 
(Southern Biotech). Sections were imaged using a XC30 camera connected to a BX53 
microscope (Olympus) or a FluoView1000 confocal microscope (BX61; Olympus). 
To detect BDA-labeled axons in light level, sections were incubated with 0.6% hydrogen 
peroxide in methanol to block endogenous peroxidase activity for 30 min at RT and washed in 
TBS. Sections were incubated overnight at 4°C with avidin–biotinylated peroxidase complex in 
TBS (Elite kit, 1:100; Vector Laboratories). After several washes, sections were maintained in a 
solution of diaminobenzidine with nickel chloride and hydrogen peroxide (Peroxidase substrate 
kit; Vector Laboratories) for 5-10 min before additional washing at RT. Sections were 
dehydrated and coverslipped with Cytoseal 60 (Thermo Fisher Scientific). 
 
2.8.Quantification of axon profiles within and beyond the scaffold 
The number of axons within the scaffold capillaries was counted in 2 out of 14 series by a person 
blinded to treatment conditions. Immunolabeled axons in all capillaries crossing imaginary lines 
perpendicular to the rostral-caudal axis of the hydrogel at 100 µm, 500 µm and 1000 µm from the 
rostral edge as well as 100 µm and 500 µm from the caudal edge of each section were counted at 
20× magnification to quantify βIII-tubulin labeled axons. The number of axons per mm2 
hydrogel was calculated using the following equation: 
	N =
∑	

,,∗				()∗∑						 		()
. 
BDA and 5-HT-labeled axons in the hydrogel were quantified in one out of 14 serial sections. 
The maximum number of axons observed at any distance in every channel was quantified 
separately in the rostral and caudal half of the hydrogel and divided by the total number of 
channels present in the section. Axons extending in the same channel were only counted once. The 
number of axons per channel was averaged for each animal and means of each group were used for 
statistical comparison. BDA-labeled axonal profiles in the ipsilateral host tissue crossing 
imaginary lines placed perpendicular to the longitudinal axis of the spinal cord caudal to the 
hydrogel edge at 100, 200, 400, 600, 800, 1000 and 1200 µm were also counted in 2 out of 14 
serial sections. 
 
2.9.Statistics 
All data are presented as mean ± standard error (SEM) and GraphPad Prism 5.01 software was 
used for all statistical analyses. Comparisons between groups were made using unpaired 
Student’s t-test or non-parametric analysis for data not normally distributed (Kruskal-Wallis test 
followed by Dunn’s test). One-way ANOVA with Tukey’s post hoc analysis or two-way 
ANOVA with Bonferroni post hoc tests were used for multiple comparisons. A significance 
criterion of p<0.05 was used. 
 
3. Results 
3.1.Integration of SC-seeded alginate hydrogels in the host spinal cord 
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For hydrogels to be suitable as implant in the injured spinal cord, they must integrate into host 
tissue without excessive scarring, maintain its integrity over the period of axonal regeneration 
and allow for sufficient diffusion of nutrients to support cell survival. The architecture of 
alginate hydrogels remained stable at 4 weeks (Fig. 2A-C) and 8 weeks (Suppl. Fig 4, Fig. 8) 
post implantation into a cervical hemisection, the longest time point examined. Scaffolds filled 
the spinal cord lesion site, numerous grafted GFP-labeled SCs survived within the channels and 
the adjacent tissue, integrating the hydrogel at the rostral and caudal ends of the lesion with the 
host spinal cord (Fig. 2C-F). GFAP-labeled astrocytes showed mild hypercellularity around the 
hydrogel with rare cavitation between the scaffold and the host tissue. 
 
3.2.Characterization of regulated GFP and BDNF expression in vitro and in vivo 
To characterize the tet-regulated plasmids, we first transfected 293T cells with 
rAAV-rtTAV16-GFP or -BDNF plasmid (Suppl. Fig. 1A). A significantly larger number of 
GFP+ cells was observed in the group transfected with rAAV-rtTAV16-GFP (henceforth referred 
to as rAAV5-GFP) and treated with Dox (Suppl. Fig. 1B-F) when compared to cells transfected 
with the same plasmid without Dox treatment. After transfection with rAAV-rtTAV16-BDNF 
(henceforth referred to as rAAV5-BDNF), BDNF expression was upregulated 26-fold in cells 
receiving Dox in the culture medium (3.31±0.06 ng/ml per 24h) compared to cells that did not 
receive Dox. No BDNF was detected in cells transfected with the rAAV5-GFP control plasmid 
(Suppl. Fig. 1G). 
Based on these results, animals were injected with rAAV5-GFP 4 mm caudal to the hydrogel 
implant and continuously received Dox (2 mg/ml) or only 5% sucrose in the drinking water for 4 
weeks. Only a limited number of cells confined primarily to the virus injection site showed GFP 
fluorescence in animals that were not treated with Dox (Fig. 3A, C). In contrast, Dox-treated 
animals exhibited strong GFP fluorescence in the spinal cord ipsilateral to the lesion, which 
extended from the injection site to the graft/host border as well as ~5 mm caudal from the 
injection site (in total ~9 mm from the hydrogel) (Fig. 3B, D, E). Based on the morphology of 
GFP-labeled cells and double labeling with neuronal, astroglial and oligodendroglial markers, 
infected cells were primarily glia, but also host neurons (Suppl. Fig. 2). No GFP-labeled cells 
were observed within the channels of either rAAV5-GFP injected groups. 
Measuring overall BDNF levels by ELISA in an 8 mm ipsilateral spinal cord segment caudal to 
the lesion in animals injected with rAAV5-BDNF showed similar results. The highest levels 
were measured in animals that received Dox. In the absence of Dox, BDNF expression in 
animals injected with rAAV5-BDNF showed a minor increase, however did not significantly 
differ from BDNF levels in animals injected with rAAV5-GFP (Fig. 3F). BDNF levels in the 
alginate hydrogel were only slightly elevated in subjects receiving rAAV5-BDNF and Dox 
treatment with no significant difference between all groups (Fig. 3G). Given that animals 
injected with GFP virus did not indicate any GFP-labeled cells within the graft, it is likely that 
any BDNF in the alginate is derived from Schwann cells and BDNF diffusion from the adjacent 
host tissue. 
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Importantly, the spread of rAAV5-BDNF established a neurotrophic gradient within the spinal 
cord. BDNF levels in the first 9 mm caudal to the graft were significantly increased in animals 
after Dox treatment. The peak level of BDNF was detected directly at the vector injection site, 
with BDNF levels decreasing in rostral and caudal direction, although a slight increase in BDNF 
levels was observed close to the lesion. In the absence of Dox, animals showed a mild, but 
insignificant increase of BDNF at the injection site and at the graft/host interface (Fig. 3H). 
Taken together, these data show that gene expression can be tightly regulated by Dox both in 
vitro and in vivo. 
 
3.3.Distal delivery of BDNF increases axonal regeneration into alginate hydrogels 
To analyze overall axonal growth into the scaffold, axons were immunolabeled for βIII-tubulin. 
Labeled axons entered the scaffold from both sides and mostly filled the entire length of 
SC-seeded channels in all groups (Fig. 4A). Axons within the channels extended along SCs in a 
highly linear pattern parallel to the longitudinal axis of the channel wall irrespective of distal 
virus injection (Fig. 4B-D). Most axons were located in the center of each channel rather than 
directly attaching to the capillary wall, similar to our previous findings in alginate hydrogels 
seeded with BMSCs [11]. Confocal microscopy showed that axons were in close proximity to 
grafted SCs (Fig. 4E-F). 
Quantification of axons within the channels indicated that the number of axons in the middle of 
the hydrogel was not significantly different from the number at the rostral and caudal end of the 
alginate channels within each group. Thus, axons grew forward persistently without attenuation 
in number with increasing distance from the edge.  
When BDNF expression in the caudal host parenchyma was turned on, a 1.5-2-fold increase in 
the number axons per channel area was observed in comparison to subjects without Dox 
treatment or GFP control animals four weeks after engraftment. In contrast, when BDNF 
expression was continuously switched off (-Dox), the number of axons was only slightly higher 
compared to animals that received GFP virus, however this difference was not significant (Fig. 
4G, p>0.05 at all distances) after 4 weeks. Therefore, caudal BDNF expression augmented 
axonal growth in the alginate hydrogels and tet-on vectors could be turned off to a level that did 
not result in significant biological effects in vivo. 
Since virally expressed BDNF is relatively high right up to the graft interface, we hypothesized 
that increased axonal growth even at the most rostral portion of the alginate scaffold might be 
ascribed to the diffusion of BDNF into the channels. To address this hypothesis, one additional 
group of Dox-treated animals received the same volume (8 µl) of rAAV5-BDNF at a distance of 
6 mm instead of 4 mm caudal to the hydrogel to move the BDNF gradient more caudally and 
thereby limit BDNF diffusion into the implant. As the distribution of BDNF measured by ELISA 
in rAAV5-BDNF-injected animals was similar to that of GFP fluorescence in rAAV5-GFP 
injected animals (Fig. 3), for this more caudal injection AAV5-BDNF was mixed with 10% (v/v) 
of rAAV5-GFP as an indirect indicator of BDNF expression. In contrast to virus injections 4 mm 
caudal to the lesion (Fig. 3), GFP fluorescence after more distal injections did not reach the 
caudal host/graft interface and stopped 200-400 µm caudal to the lesion (Suppl. Fig. 3) 
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indicating a lower level of BDNF at the caudal edge of the hydrogel. This more distally located 
BDNF gradient failed to promote axonal regeneration into the scaffold compared to GFP virus 
injected animals (Fig. 4G, p>0.05 at all distances). Thus, for caudal BDNF virus to increase 
axonal growth, sufficiently high BDNF levels need to be present right at the caudal host/graft 
interface. 
 
3.4.Raphespinal and propriospinal axonal growth into alginate hydrogels 
Raphespinal axons from the brainstem play a vital role in modulating the activity of neural 
networks in the spinal cord and mediating locomotor function [38]. Immunolabeling for 
serotonin (5-HT), a neurotransmitter specific for raphespinal axons in the spinal cord, showed 
that 5-HT-labeled axons regenerated into and extended throughout the channels in all animals 
(Fig. 5B-F). Viral BDNF expression for 4 weeks in the caudal host parenchyma induced 
significantly more growth of serotonergic axons into the rostral half of the scaffold in 
comparison to animals that received rAAV5-BDNF without Dox treatment and GFP control 
groups regardless of Dox treatment. In the caudal half of the channels, BDNF also triggered 
more 5-HT+ axonal penetration compared to GFP control groups (Fig. 5G). However, the 
number of serotonergic axons in the channels was lower when comparing the rostral and caudal 
half of the hydrogel, and 5-HT+axons that extended up to the caudal interface of the hydrogel 
failed to enter the distal host parenchyma. 5-HT+ axons were not uniformly distributed, some 
channels contained bundles of axons whereas other channels did not contain any 5HT+ axons. 
Consistent with our data of overall neurite growth (βIII-tubulin) (Fig. 4G), more caudal (6 mm) 
BDNF virus injections and Dox treatment resulted in a similar number of 5-HT+ axons as 
observed in animals with BDNF virus without Dox treatment (Fig. 5G). An increase in 5-HT+ 
axons was also observed when BDNF expression was never turned on in comparison to GFP 
control animals, but this difference failed to reach significance. 
 
Propriospinal neurons are an important part of spinal neural circuits for relay and connection 
with other tracts [39]. BDA was used as an anterograde tracer for descending propriospinal and 
other descending axons of passage in this study. BDA-labeled axons were found to regenerate 
through the scaffold, and animals that received rAAV5-BDNF injection and Dox treatment had 
the highest number of axons both in the rostral and caudal halves of the alginate graft (Fig. 
6A1-D3). In contrast to serotonergic axons, the number of BDA-labeled axons remained fairly 
constant from the rostral to the caudal half of the alginate in animals with BDNF expression 
turned on. Group differences observed within the graft were also found for axons within and 
beyond the scaffold (Fig. 6F-G). Consistent with 5-HT and βIII-tubulin labeling, the number of 
BDA-labeled axons decreased when the BDNF gradient was moved more caudally (6 mm) (Fig. 
6E1-E3 and F-G). 
Taken together, growth of descending axons is increased within hydrogel scaffolds when BDNF 
expression is turned on sufficiently close to the alginate hydrogel for 4 weeks, but axons do not 
extend for significant distances beyond the lesion. 
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3.5.Sustained BDNF expression for axonal regeneration into alginate hydrogels 
To determine whether longer BDNF expression would modify axonal growth responses after 
implantation of SC-seeded alginate hydrogels, a separate cohort of animals was allowed to 
survive for 8 weeks post-lesion after injection of BDNF virus (mixed with 10% GFP virus). 
Animals underwent continuous (8wks +Dox) or transient (4wks +Dox/4wks -Dox) Dox 
treatment. Animals that were treated with Dox for 8 weeks showed virus-infected GFP+ cells 
from the caudal injection site right up to the edge of the hydrogel as observed for shorter time 
points. In animals that received Dox only for the first 4 weeks, GFP fluorescence was absent four 
weeks after withdrawal of Dox, indicating that viral gene expression can be switched off in vivo 
(Suppl. Fig. 4). 
Overall axonal growth (βIII-tubulin labeling) was not altered by the longer time points. 
Compared to animals killed after 4 weeks of BDNF expression, continuous (8wks +Dox) or 
transient (4wks +Dox/4wks -Dox) Dox treatment resulted in a similar number of axons within 
hydrogel channels that remained rather constant at the rostral and caudal end as well as in the 
middle of the hydrogel (Fig. 7A, D). Similar results were observed for descending axons traced 
with BDA (Fig. 7C, F). However, the regrowth of 5-HT-labeled serotonergic axons was 
significantly enhanced at the 8 week time point after rAAV5-BDNF injection. Irrespective of 
BDNF being persistently (8wks +Dox) or transiently (4wks +Dox/4wks -Dox) expressed, the 
number of serotonergic axons was significantly increased in comparison with animals that had 
BDNF expression turned on for only 4 weeks (4wks +Dox) (Fig. 7B, E). Therefore, extending 
BDNF expression beyond 4 weeks has no overall additive effect, however enhanced growth of 
some axonal populations given additional time is possible even in the absence of higher BDNF 
levels. 
 
3.6.Modification of the graft/host interface by SC injection into the host spinal cord 
In the experiments described above, most of the regenerating descending axons were confined to 
the caudal interface rather than re-entering into the host parenchyma even in the presence of a 
distal BDNF gradient and extended periods for long distance growth (Fig. 6G and Fig. 8A). The 
fibroglial scar surrounding the graft is one potential obstacle impeding axonal regeneration into 
the distal spinal cord [2, 40]. To modify the permissiveness of the scar at the caudal 
hydrogel/graft interface and to further facilitate axonal growth, we additionally injected 
GFP-transgenic SCs into the host tissue 1 mm caudal to the alginate hydrogel in one group of 
animals that received caudal rAAV5-BDNF injection. Animals were treated with Dox and 
survived for 8 weeks. SCs seeded within the hydrogel were not GFP-labeled. Injected GFP+ 
transgenic SCs migrated from the injection site, and some entered the capillaries of the hydrogel 
(Fig. 8F) even approaching the rostral graft/host interface. Interestingly, the combination of SC 
injection and BDNF expression for 8 weeks in the caudal spinal cord not only significantly 
increased the overall number of βIII-tubulin-labeled axons regenerating into the hydrogel (Fig. 
7D), but also doubled the number of 5-HT- (Fig. 7E) and BDA-labeled axons (Fig. 7F) growing 
into the channels compared to animals that underwent the same treatment without additional SC 
injection. 
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Most importantly, more BDA-labeled descending axons penetrated the caudal alginate/host 
interface and entered the host parenchyma when the caudal spinal cord was injected with SCs 
and BDNF expression was turned on for 8 weeks (Fig. 8E). A significantly increased number of 
BDA-labeled axons were found up to 1200 µm beyond the caudal hydrogel interface and 
extended along the migration pathway of injected SCs, which were intermingled with host 
astrocytes. A small portion of axons was also detected in the caudal host parenchyma at a long 
distance (>2000 µm) further caudal than the SC injection site (Fig. 8B and D-F). 
 
4. Discussion 
The present study systematically investigated the parameters needed to achieve axonal 
regeneration across an anisotropic capillary alginate hydrogel in a lateral hemisection lesion. Our 
data indicate that 1) transient expression of BDNF is sufficient to sustain regenerated axons, 2) 
some axonal populations continue to show increased growth beyond 4 weeks post-lesion even 
when BDNF expression has been turned off and 3) additional grafting of SCs beyond the lesion 
site is essential for axons to bridge across the lesion and to re-enter the caudal host tissue.  
In previous decades, biomaterials with different structural properties have been investigated in 
combination with a variety of strategies to facilitate axonal growth across a lesion after SCI [41, 
42]. One major advantage of biomaterials with linearized channels is the ability to guide axonal 
growth in a defined linear pattern allowing for more axons to regenerate across the lesion 
towards the distal host tissue for further sprouting and potential new connections [40]. In 
addition, channels provide space for the delivery of cells and bio-active molecules to improve 
therapeutic efficacy. Increased axonal regrowth was detected after implantation of 
poly(D,L-lactide-co-glycolide) (PLGA) scaffolds seeded with human mesenchymal stem cells into 
the channels [43]. Similar results were observed by engraftment of agarose scaffolds with 
encapsulated BDNF [44] or pre-seeded with BMSCs overexpressing NT-3 [40] in uniaxial 
channels. However, axonal regeneration terminated at the graft/host interface in most studies 
rather than extending into the host spinal cord to make new synaptic connections. The reactive 
cell matrix forming around a graft is a prominent obstacle impeding axonal growth into the host 
parenchyma [40].  
To overcome this impediment, we first aimed to generate a BDNF gradient caudal to the graft to 
induce axonal growth beyond the alginate hydrogel. In previous studies using a cell suspension 
graft at the lesion site and lentiviral NT-3 gene transfer rostral to the lesion, we have shown that 
gradients of neurotrophins can enhance short distance bridging of ascending sensory axons [45]. 
Distal delivery of BDNF has also been shown to promote some short distance growth of 
reticulospinal axon populations when lesions extended no more than 0.5-1 mm [31]. The current 
results also demonstrate that viral BDNF expression caudal to the lesion enhances axonal growth 
and augments the pro-regenerative effect of alginate channels pre-seeded with SCs. In addition, 
more than 50% of raphespinal and 80% of BDA-labeled descending axons found in the rostral 
half of the alginate biomaterial continue to extend over the caudal half of the 2 mm alginate 
hydrogel. Diffusion of BDNF from the caudal host tissue into the channels likely contributed to 
the increased growth as animals injected with rAAV-GFP never showed any transfected cells 
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within the graft. Yet, similar to studies using agarose or alginate scaffolds with channels in 
combination with cellular BDNF delivery within the biomaterial [11, 46], most of the descending 
axons failed to extend beyond the alginate hydrogels even when BDNF expression was extended 
up to 2 months post-injury (Fig. 6-7). It is possible that the widespread increase in BDNF 
established by rAAV5 caudal to the lesion does not provide a sufficiently steep growth factor 
gradient to attract axons beyond the caudal scar tissue. Delivery of neurotrophic factors using 
less diffusible vectors, e.g. rAAV2 or lentiviral vectors may help to create a more effective, 
localized gradient and propel axonal penetration into the host tissue. 
The second strategy in this study to enhance bridging axonal regeneration was the injection of 
syngeneic SCs in the caudal spinal cord in combination with BDNF delivery. Caudally injected 
SCs generated a cellular trail from alginate channels into the host tissue enabling BDA-traced 
descending axons to extend into the adjacent caudal spinal cord identified by GFAP labeling. 
Distal Schwann cell injections appeared to disrupt the distinct astroglial border usually found 
directly adjacent to the hydrogel. Axons extending along these Schwann cells were therefore able 
to reach more distal areas of the host spinal cord, where astrogliosis is less prevalent and more 
favorable for axonal bridging. Surprisingly, caudal SC injection also increased descending axon 
growth into the alginate. Given that SCs migrated towards the hydrogel, entered the channels, 
and often even approached the rostral host/graft interface, it is possible that the injected SCs 
served as an exogenous “cell bank” and supplemented dying SCs pre-seeded within the scaffold. 
From other studies, it is known that a large proportion of SCs grafted to the injured spinal cord 
gradually die via apoptosis [47]. Alternatively, the injected SCs might have been transfected by 
rAAV5-BDNF injected further caudally and thereby magnified the regenerative response of 
axons when they migrated into the channels. Compared to our previous studies using alginate 
hydrogels that were filled with bone marrow stromal cells and grafted in the same lesion model, 
seeding channels with SCs not only promoted growth of a greater number of axons, but axonal 
extension was also sustained continuously throughout the channels and a decrease in axon 
number in the center of the hydrogels was not observed [11]. Due to the nature of the lesion 
(lateral hemisection), we cannot definitively exclude the possibility that some BDA-labeled 
axons found caudal to the lesion site were derived from collateral sprouting from the 
contralateral side. However, some axons could be clearly traced from alginate channels into the 
caudal spinal cord and the decline in axon numbers with increasing distance from the alginate 
also suggests that these axons had extended through the hydrogel. Studies in complete 
transections will be better suited to answer this question by histological and electrophysiological 
means. 
In contrast to most previous studies using viral neurotrophin delivery, the current study used a 
tetracycline-inducible vector for BDNF expression. The temporal regulation of BDNF 
expression to enhance axonal growth is essential for clinical translation, given the adverse effects 
observed with long-term BDNF delivery [30, 31]. The controlled expression allowed us to 
determine whether high levels of BDNF for 2 months results in superior axonal growth 
compared to short-term one month delivery. Neither overall axonal growth, nor growth of 
serotonergic nor other BDA-labeled descending tracts differed between short and long-term 
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delivery. However, we observed more axon growth at 2 months compared to 1 month 
independent of high BDNF levels indicating that either SC-derived factors or very small BDNF 
levels from leaky vector-derived gene expression are sufficient to further improve regenerative 
growth. These longer-term studies also confirmed the excellent bio-compatibility of 
alginate-based hydrogels as previously reported at shorter time points [11]. As a crucial structure 
for axonal guidance, the linearized microstructure within the scaffold was stable for at least 8 
weeks after in vivo implantation. No obvious cavities were detected around the scaffold, which is 
beneficial for axonal growth and cellular survival (Figs. 2 and 4).  
In the current experiment, animals were not tested for behavioral recovery. Lateral hemisection 
lesions extending over 2 mm at C5 destroy many neurons at segmental level (motor neurons, 
interneurons) required for upper forelimb movement and even very small differences in the 
mediolateral lesion extent possibly sparing some corticospinal axons profoundly influence 
functional outcomes. Small gains in motor performance due to regenerated axons might therefore 
not be detectable. While the current combinatorial strategy allows for the re-entry of axons into 
the host tissue, a premise for synapse formation and functional restoration [48], examining 
regeneration and functional recovery in complete transections would be better suited to prove 
that regenerated axons causally underlie any behavioral effects. 
 
5. Conclusion 
Alginate hydrogels with anisotropic capillaries support the survival of grafted SCs and guide 
supraspinal and propriospinal descending axons through and beyond the lesion site. The number 
of axons bridging the lesion significantly increases when caudal BDNF expression is activated. 
A combination of SC injection and BDNF overexpression in the caudal spinal cord further 
promotes axonal growth and penetration into the host parenchyma. Future studies will 
investigate the efficacy of the alginate hydrogel-based transplantation after SCI to improve 
functional outcomes. 
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FIGURE LEGENDS 
Fig. 1. Lesion paradigm and experimental procedures. (A) Schematic diagram of the 
experimental design. A 1.5-2 mm long segment of the spinal cord was removed unilaterally at 
the C5 level before implanting a Schwann cell (SC)-seeded alginate scaffold. Subsequently, viral 
vectors (yellow) for the regulatable expression of GFP (rAAV5-GFP) or BDNF (rAAV5-BDNF) 
were injected into the caudal spinal cord ipsilateral to the lesion. SCs (blue) were also injected 
into the caudal spinal cord in one group. Biotinylated dextran amine (BDA, red) was injected in 
the spinal cord rostral to the lesion to trace descending axons three or seven weeks post-lesion. 
(A1) Cross-sectional and (A2) longitudinal view of the capillary lumen. (B) After a hemisection 
lesion (arrowhead, ~2 mm in length) of the rat spinal cord, (C) the alginate scaffold loaded with 
SCs (white arrow) was grafted into the lesion and (D) virus (*) or SCs (black arrow) were 
injected into the spinal cord caudal to the scaffold using a glass capillary. Scale bar: 300 µm in 
(A1); 500 µm in (A2). 
 
Fig. 2. Integration of alginate hydrogels and Schwann cell (SC) survival. (A) Dorsal and (B) 
ventral view of the scaffold (arrows) in the spinal cord 4 weeks after engraftment. (C) Nuclear 
staining (DAPI) indicates that scaffold channels are filled with cells, and cavities at the host/graft 
interface are very limited in number and size. (D) Four weeks after engraftment, GFP-labeled 
SCs (green) survive within and around the alginate scaffold, connecting the scaffold to the host 
tissue identified by GFAP labeling (gray). Higher magnifications of the graft/host interface 
(dashed lines) are shown in (E, F). In (E), stars (*) label cell-seeded channels and triangles (∆) 
indicate the walls of the scaffold. Scale bar: 500 µm in (C, D); 100 µm in (E, F). 
 
Fig. 3. Characterization of tet-regulated GFP and BDNF expression in vivo. (A, B) GFP 
fluorescence (green) in the spinal cord of animals injected with rAAV5-GFP. (A) Only a few 
GFP expressing cells are found around the injection site in animals without doxycycline (Dox) 
treatment. (B) In contrast, strong GFP fluorescence is observed in Dox-treated animals spreading 
from the GFP virus injection site to the caudal graft/host interface (dashed line). (C-E) Higher 
magnification of the areas boxed in (A, B). Arrows in (A, B) indicate virus injection site. (F) 
Overall BDNF levels in the ipsilateral caudal spinal cord quantified by ELISA indicates 
significant higher BDNF levels in Dox-treated animals that received rAAV5-BDNF injection 
(***p<0.001, one-way ANOVA followed by Tukey’s post hoc analysis). (G) Differences in 
BDNF levels within the alginate scaffolds did not reach significance (n.s, not significant). (H) 
rAAV5-BDNF injection in the spinal cord established a BDNF gradient with highest levels 
around the injection site (***p<0.001; two-way ANOVA followed by Bonferroni post hoc test). 
Scale bar: 500 µm in (A, B); 100 µm in (C-E). Inset in (H) indicates the tissue (yellow) used for 
BDNF ELISA. 
 
Fig. 4. Axonal growth into SC-seeded alginate scaffolds 4 weeks post-implantation. (A) 
βIII-tubulin (red) immunolabeling of the lesion site in an animal that was implanted with an 
alginate hydrogel seeded with GFP-transgenic SCs and received caudal BDNF virus injection 
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and Dox treatment. (B-E) Higher magnification of areas boxed in (A) show similar numbers of 
βIII-tubulin-labeled axons (red) at (B) the rostral, (C) center and (D) caudal area of the alginate 
hydrogel extending along GFP-positive SCs (green) in the capillaries of the scaffolds. Dashed 
lines in (B) and (D) indicate edges of the hydrogel. (E) Confocal imaging (z-stack) and (F) cross 
plane of the area indicated by the dashed line in (E) indicates axons in the capillaries are in close 
contact or ensheathed by grafted GFP-positive SCs (arrowheads). (G) Quantification of axons 
within the scaffolds indicates significant higher number of axons at all distances in animals that 
received BDNF virus 4 mm caudal to the scaffold when gene expression was turned on 
(***p<0.001 vs GFP –Dox; ###p<0.001 vs GFP +Dox; &p<0.05, &&p<0.01 vs BDNF -Dox; 
^p<0.05, ^^p<0.01, ^^^p<0.001 vs BDNF/+Dox (6mm); two-way ANOVA followed by 
Bonferroni post hoc test). Scale bar: 500 µm in (A); 100 µm in (B-D); 20 µm in (E); 4 µm in (F). 
 
Fig. 5. Regeneration of serotonergic axons into alginate scaffolds. (A) Schematic 
representation of the scaffold in the spinal cord and location (box) where images in (B-F) were 
taken. (B-F) Serotonergic (5-HT-labeled) axons enter the scaffolds and extend along the 
channels. (G) Quantification of 5-HT-labeled axons within the scaffolds indicates higher number 
of 5-HT-positive axons in animals with BDNF expression turned on (*p<0.05; **p<0.01; 
***p<0.001; one-way ANOVA followed by Tukey’s post hoc analysis). Scale bar: 100 µm in 
(B-F). 
 
Fig. 6. Penetration of descending BDA-labeled axons through alginate scaffolds. (A1-E3) 
Propriospinal and other descending axons traced with BDA grow through the scaffolds in 
rostro-caudal direction. Schematics on top depict regions where images were taken. Dashed lines 
in (A1, B1, C1, D1, E1) and (A3, B3, C3, D3, E3) indicate the rostral and caudal edges of the 
scaffold, respectively. Axons extending through the scaffold terminate just caudal to the scaffold. 
(F) Quantification of BDA-labeled descending axons regenerated into the rostral and caudal half 
of scaffolds shows significant higher numbers in animals with BDNF virus when gene 
expression is turned on. (G) Similar differences are observed for BDA-labeled axonal profiles 
just beyond the caudal edge of scaffolds (*p<0.05; **p<0.01; ***p<0.001; one-way ANOVA 
followed by Tukey’s post hoc analysis). Scale bar: 100 µm in (A1-E3). 
 
Fig. 7. Long-term BDNF expression combined with SC injection for axonal growth within 
the alginate hydrogel. Representative images for (A) overall axon growth, (B) serotonergic 
axons and (C) BDA-labeled descending axons within the scaffold 8 weeks post-lesion with 
continuous caudal BDNF expression. Schematics on top of (B, C) depict regions where images 
were taken. (D-F) Quantification of (D) overall axonal growth, (E) serotonergic axons and (F) 
descending propriospinal axons within the channels. Significantly more axons are found in 
animals that received rAAV5-BDNF when gene expression is turned on and SCs are injected 
caudal to the lesion (*p<0.05, **p<0.01 vs rAAV5-BDNF/4wks +Dox; #p<0.05, ##p<0.01 vs 
rAAV5-BDNF/4wks +Dox/4wks -Dox; &p<0.05, &&p<0.01 vs rAAV5-BDNF/8wks +Dox; 
two-way ANOVA followed by Bonferroni post test). The same group also shows the highest 
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level of serotonergic and BDA-labeled axons (*p<0.05; **p<0.01; ***p<0.001; one-way 
ANOVA followed by Tukey’s post hoc analysis). Dashed line in (C) indicates caudal edge of the 
hydrogel. Scale bar: 500µm in (A); 100 µm in (B, C). 
 
Fig. 8. Caudal injection of SCs allows for descending BDA-labeled axons to extend beyond 
the alginate scaffolds. (A, C) Most BDA-labeled axons (red) fail to extend beyond the graft/host 
interface (dashed line) demarcated by GFAP-labeled astrocytes (cyan) in animals that received 
SC-seeded alginate scaffolds and caudal BDNF virus injection despite survival for 8 weeks in the 
presence of doxycycline (gene expression turned on). (B, D) In contrast, descending 
BDA-labeled axons regenerate through the entire hydrogel and the caudal interface (dashed line) 
into the host tissue identified by GFAP labeling into and beyond areas occupied by (F) injected 
GFP+ SCs in animals with caudal BDNF virus injection and additional SC injection. Axons 
(arrowheads) elongate into the distal host spinal cord beyond the SC grafts. (E) Quantification of 
axons regenerated beyond the caudal edge of the scaffold (*p<0.05; **p<0.01; ***p<0.001; 
one-way ANOVA followed by Tukey’s post hoc analysis). SC injection site is indicated by 
arrow. Scale bar: 300 µm in (A-D, F). 
 
Suppl. Fig. 1. Vector map and in vitro regulation of gene expression. (A) Plasmid map of the 
tet-regulated AAV vector. Expression of the reverse tetracycline (tet) transactivator (rtTA) and 
enhanced GFP (eGFP) or human BDNF (huBDNF) is driven by a bi-directional tet-regulated 
promoter (ptetbidi). ITR, inverted terminal repeat; SV40pA, SV40 polyadenylation signals. (B-E) 
GFP fluorescence was detected in 293T cells 24h after transfection with the 
rAAV-rtTAV16-GFP plasmid, but not rAAV-rtTAV16-BDNF plasmid. (F) Quantitative analysis 
shows a significant increase of GFP+ cell number when the wells are treated with 1 µg/ml Dox. 
(G) BDNF levels are significantly higher in the supernatant of cells transfected with 
rAAV-rtTAV16-BDNF and treated with Dox (+Dox) (*p<0.05; ***p<0.001; Kruskal-Wallis 
followed by Dunn’s test). Scale bar: 100 µm in (B-E). 
 
Suppl. Fig. 2. Characterization of rAAV5-GFP infected cells. Double immunofluorescence 
labeling for GFP and glial and neuronal markers shows co-localization of GFP with (A, B) 
astrocytes (GFAP) and (C, D) oligodendrocytes (olig2). Confocal images confirm co-localization 
of (E) NeuN and (F) GFAP with GFP. Arrows indicate examples of double-labeled cells. Scale 
bars: 100 µm in (A-D), 50µm in (E, F). 
 
Suppl. Fig. 3. Diffusion pattern of tet vectors after a more caudal (6 mm) injection. (A) GFP 
fluorescence in the spinal cord after injection of rAAV5-BDNF containing 10% (v/v) of 
rAAV5-GFP 6 mm caudal to the lesion. GFP-labeled cells can be detected in the caudal spinal 
cord, but do not reach the graft/host interface (dashed line). (B, C) Higher magnification of the 
areas boxed in (A). Scale bar: 500 µm in (A); 100 µm in (B, C). 
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Suppl. Fig. 4. Long-term regulation of tet vectors in vivo. (A, B) GFP fluorescence in the 
spinal cord after injection of rAAV5-BDNF containing 10% (v/v) rAAV5-GFP 4 mm caudal to 
the lesion. (A) No GFP+ cells are visible in the caudal spinal cord of animals treated with 
doxycycline (Dox) for 4 weeks followed by withdrawal of Dox for 4 weeks. (B) GFP 
fluorescence can be easily detected in the caudal spinal cord of animals continuously treated with 
Dox for 8 weeks. (C-E) Higher magnification of the areas boxed in (A, B). Scale bar: 500 µm in 
(A, B); 100 µm in (C-E). 
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Recovery from spinal cord injury is poor due to the limited regeneration observed in the adult 
mammalian central nervous system. Biomaterials, cell transplantation and growth factors that can 
guide axons across a lesion site, provide a cellular substrate, stimulate axon growth and have 
shown some promise in increasing the growth distance of regenerating axons.  In the present 
study, we combined an alginate biomaterial with linear channels with transplantation of Schwann 
cells within and beyond the lesion site and injection of a regulatable vector for the transient 
expression of brain-derived neurotrophic factor (BDNF).  Our data show that only with the full 
combination axons extend across the lesion site and that expression of BDNF beyond 4 weeks 
does not further increase the number of regenerating axons.   
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Table 1: Experimental groups 
Gene 
regulation rAAV5
*
 
SC seeding 
in the 
hydrogel 
Caudal SC 
injection 
# of animals 
Histological 
analysis 
BDNF 
ELISA 
4 weeks on  BDNF GFP-SC - 6 10 
4 weeks on  BDNF§ (6 mm) WT-SC - 6 
 
4 weeks off  BDNF GFP-SC - 6 7 
4 weeks on GFP WT-SC - 6 3 
4 weeks off GFP WT-SC - 6 3 
8 weeks on BDNF WT-SC GFP-SC 6 
 
8 weeks on BDNF§ GFP-SC - 8 
 
4 weeks on /  
4 weeks off BDNF
§
 WT-SC - 6 
 
*Virus was injected in the host spinal cord tissue 4 mm caudal to the graft/host interface unless 
otherwise indicated. 
§Virus containing 10% (v/v) rAAV5-GFP. 
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